7 completed, 1 active not recruiting, 1 suspended, 1 terminated. 10 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 7, Active not recruiting 1, Suspended 1, Terminated 1 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
Follow Prostatic Neoplasm: new trials by email Literature Review of Prostatic Neoplasm trials Research Report on Prostatic Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness Dietary recommendations, Time-restricted eating - Prostatic Neoplasm, Survivorship | Phase 1 / Phase 2 | Active not recruiting | University of Maryland, Baltimore | 30 | 2024-01-29 | 2026-01-27 |
| EBRT + Lu-PSMA for N1M0 Prostate Cancer 177Lu-PSMA-617, EBRT - Prostatic Neoplasm | Phase 1 | Completed | The Netherlands Cancer Institute | 14 | 2021-12-20 | 2025-12-10 |
| Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit - Prostatic Neoplasm | Phase 1 | Completed | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 3 | 2019-01-24 | 2020-10-26 |
| Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy 18F-DCFPyL, Tumor Irradiation, Prostate + tumor irradiation - Prostate Cancer, Prostatic Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 17 | 2018-07-05 | 2025-10-08 |
| 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer 177Lu-PSMA-R2 - Prostatic Neoplasm | Phase 1 | Terminated | Advanced Accelerator Applications | 27 | 2018-05-24 | 2025-05-13 |
| A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer EZN-4176 - Prostatic Neoplasm | Phase 1 | Suspended | Enzon Pharmaceuticals, Inc. | 150 | 2011-03-01 | 2012-12-18 |
| Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer radioimmuniguided intenstiy modulated radiotherapy - Prostatic Neoplasm | Phase 1 / Phase 2 | Completed | Mayo Clinic | 72 | 2006-10-01 | 2011-02-25 |
| Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms PF00562271 - Head and Neck Neoplasm, Prostatic Neoplasm | Phase 1 | Completed | Verastem, Inc. | 99 | 2005-12-01 | 2013-03-21 |
| Preop Conformal Radiotherapy - Prostate Pre-Operative Conformal Radiotherapy - Prostatic Neoplasm | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 15 | 2000-05-01 | 2010-08-11 |
| A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms 7-hydroxystaurosporine (UCN-01) - Breast Cancer, Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 51 | 1995-08-01 | 2008-03-04 |
Prostatic Neoplasms (10) · Breast Neoplasms (2) · Neoplasms (2) · Adenocarcinoma (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Frailty (1) · Genital Neoplasms, Male (1) · Head and Neck Neoplasms (1) · Lymphoma (1) · Neoplasm Metastasis (1) · Neoplasms by Site (1) · Pancreatic Neoplasms (1) · Prostatic Diseases (1) · Urogenital Neoplasms (1)
Genital Diseases (10) · Genital Diseases, Male (10) · Male Urogenital Diseases (10) · Urogenital Diseases (10) · Genital Neoplasms, Male (9) · Neoplasms by Site (9) · Prostatic Diseases (9) · Urogenital Neoplasms (9) · Neoplasms (8) · Breast Diseases (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
18F-JK-PSMA-7 (1) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · 5'-ACCaagtttcttcAGC-3' (1) · 7-hydroxystaurosporine (1) · PF-00562271 (1) · Pluvicto (1)
National Cancer Institute (NCI) (2) · Advanced Accelerator Applications (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Enzon Pharmaceuticals, Inc. (1) · Mayo Clinic (1) · The Netherlands Cancer Institute (1) · University Health Network, Toronto (1) · University of Maryland, Baltimore (1) · Verastem, Inc. (1)
United States (7) · Canada (2) · Australia (1) · Belgium (1) · Netherlands (1) · Spain (1) · United Kingdom (1)
Aby Buchbinder, MD (1) · Amber Kleckner, PhD (1) · Daniel Danila, MD (1) · Deborah E Citrin, M.D. (1) · Johann de Bono, MD (1) · Padraig Warde, MD (1) · Wouter V Vogel, MD, PhD (1)
PMID 36959540, PMID 38428681, PMID 42570448
2017 (1)